Stingray Therapeutics has a total of 32 patents globally, out of which 5 have been granted. Of these 32 patents, more than 75% patents are active. Europe (EPO) is where Stingray Therapeutics has filed the maximum number of patents, followed by United States of America and South Korea. Parallelly, the USA seems to be the main focused R&D center of Stingray Therapeutics and is also the origin country of the firm.
Stingray Therapeutics was founded in the year 2018 by Jonathan Northrup and Sunil Sharma. The company is a biotech firm that develops immunotherapies to treat various types of cancer.
Do read about some of the most popular patents of Stingray Therapeutics which have been covered by us in this article and also you can find Stingray Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Stingray Therapeutics patent portfolio.
How many patents does Stingray Therapeutics have?
Stingray Therapeutics has a total of 32 patents globally. These patents belong to 7 unique patent families. Out of 32 patents, 24 patents are active.
How Many Patents did Stingray Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Stingray Therapeutics Applications Filed | Stingray Therapeutics Patents Granted |
| 2022 | 3 | 1 |
| 2021 | 18 | 1 |
| 2020 | 3 | 1 |
| 2019 | 3 | – |
| 2018 | 4 | – |
| 2017 | – | – |
| 2016 | – | – |
| 2015 | – | – |
| 2014 | – | – |
| 2013 | – | – |
| 2012 | – | – |
| 2011 | – | – |
How many Stingray Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Stingray Therapeutics File in Different Countries?
Countries in which Stingray Therapeutics Filed Patents
| Country | Patents |
| Europe | 6 |
| United States Of America | 5 |
| Korea (South) | 3 |
| New Zealand | 1 |
| Taiwan | 1 |
| Canada | 1 |
| Mexico | 1 |
| Austria | 1 |
| South Africa | 1 |
| Australia | 1 |
| Brazil | 1 |
| Argentina | 1 |
| Hong Kong (S.A.R.) | 1 |
| Israel | 1 |
Where are Research Centres of Stingray Therapeutics Patents Located?
The R&D Centre of Stingray Therapeutics is in the US.
Most Cited Stingray Therapeutics Patent
US11407729B2 is the most popular patent in the Stingray Therapeutics portfolio. It has received 3 citations so far.
List of Stingray Therapeutics Patents
| Stingray Therapeutics Patents | Title |
| US11591313B2 | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| US11407729B2 | Quinoline And Quinazoline Compounds And Methods Of Use Thereof |
| US11142524B2 | Substituted-3H-Imidazo[4,5-C]Pyridine And 1H-Pyrrolo[2,3-C]Pyridine Series Of Novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulators As Cancer Immunotherapeutics |
| US10689376B2 | Substituted-3H-Imidazo [4,5-C] Pyridine And 1H-Pyrrolo[2,3-C]Pyridine Series Of Novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulators As Cancer Immunotherapeutics |
| US20230183212A1 | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| EP3658138B1 | Substituted-3H-Imidazo(4,5-C)Pyridine And 1H-Pyrrolo(2,3-C)Pyridine Series Of Novel Ectonucleotide Pyrophsphatase/Phosphodiestrase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulator As Cancer Immunotherapeutics |
| EP4259148A1 | Phosphonates As Inhibitors Of Enpp1 And Cdnp |
| EP4255425A1 | Imidazole Compounds As Inhibitors Of Enpp1 |
| EP4100394A1 | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| EP3941459A4 | Quinoline And Quinazoline Compounds And Methods Of Use Thereof |
| EP3829561A4 | Substituted-3H-Imidazo[4,5-C]Pyridine And 1H Pyrrolo[2,3-C]Pyridine Series Of Novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulators As Cancer Immunotherapeutics |
| CA3166485A1 | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| AU2021217148A1 | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| IL295257A | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| HK40077501A | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| KR1020230118883A | Imidazole Compounds As Enpp1 Inhibitors |
| KR1020230118602A | Phosphonates As Inhibitors Of Enpp1 And Cdnp |
| MX2022009534A | Ectonucleotide Pyrophosphatase/Phosphophiesterase 1 (Enpp1) Inhibitors And Methods Of Use Thereof |
| KR1020220138399A | Inhibitors Of The Exonucleotide Pyrofospatase/Pospodi Esterase 1 (Enpp1) And How To Use It |
| BR112022014981A2 | Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) Inhibitors And Methods Of Use Thereof |
| ZA202208541A | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| AR121269A1 | Ectonucleotide Pyrophosphatase / Phosphodiesterase 1 (Enpp1) Inhibitors And Methods Of Use Thereof |
| TW202140439A | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| NZ790825A | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| AT1561116T | Substituierte-3H-Imidazo(4,5-C)Pyridin- Und -1H-Pyrrolo(2,3-C)Pyridin-Reihen Von Neuartigen Ectonukleotid-Pyrophsphatase/Phosphodiestrase-1 (Enpp1) Und Stimulator Für Modulator Von Interferon-Genen (Sting) Als Krebsimmuntherapeutika |
| WO2022125613A1 | Phosphonates As Inhibitors Of Enpp1 And Cdnp |
| WO2022125614A1 | Phosphonates As Inhibitors Of Enpp1 And Cdnp |
| WO2022119928A1 | Imidazole Compounds As Inhibitors Of Enpp1 |
| WO2021158829A1 | Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof |
| WO2020190912A1 | Quinoline And Quinazoline Compounds And Methods Of Use Thereof |
| WO2019023635A8 | Substituted-3H-Imidazo(4,5-C)Pyridine And 1H-Pyrrolo(2,3-C)Pyridine Series Of Novel Ectonucleotide Pyrophsphatase/Phosphodiestrase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulator As Cancer Immunotherapeutics |
| WO2020028724A1 | Substituted-3 H-Imidazo[ 4,5-C]Pyridine And 1 H-Pyrrolo[ 2,3-C]Pyridine Series Of Novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulators As Cancer Immunotherapeutics |
What are Stingray Therapeutics’ key innovation segments?
What Technologies are Covered by Stingray Therapeutics?
The chart below distributes patents filed by Stingray Therapeutics